Supreme Court Questions SEBI Delay in Closing ₹5,100 Crore Sandesara Fraud Case
India’s Supreme Court has intervened to question why the market regulator, the Securities and Exchange Board of India (SEBI), continues to pursue legal proceedings against the Sandesara brothers despite a court-sanctioned settlement of ₹5,100 crore aimed at resolving a massive bank fraud case. The hearing, held before a bench comprising Justices J.K. Maheshwari and A.S. Chandurkar, highlighted a potential disconnect between judicial directives aimed at recovering funds and ongoing regulatory actions. The court has scheduled further examination of the complaint for March 23.
Background and Context
The dispute stems from a significant judicial development last year, when the court permitted the Sandesara brothers and their associates to seek closure of criminal proceedings after agreeing to repay ₹5,100 crore as a one-time settlement. The agreement was accepted with the consent of the central government and the Directorate of Enforcement (ED), intended to bring an end to multiple cases arising from an alleged multi-crore bank fraud. These cases had been investigated by agencies including the Central Bureau of Investigation (CBI), the Serious Fraud Investigation Office (SFIO), and the Income Tax Department. The court had observed that continuing criminal proceedings would not serve a useful purpose, particularly as the recovered funds were being returned to public sector banks.
Key Figures and Entities
The legal challenge focuses on former directors of Sterling Biotech Ltd., Nitin and Chetan Sandesara, who have petitioned against the continued regulatory action. The bench specifically questioned why SEBI appeared to be “coming in the way” of implementing the court's earlier order to close proceedings. Separately, a group of lenders led by the State Bank of India (SBI) has filed an application seeking directions for the disbursal of funds deposited by the Sandesara brothers with the court registry. The lenders have submitted a detailed chart outlining their respective claims and proposed shares in the distribution of the recovered amounts.
Legal and Financial Mechanisms
The core of the legal tension lies in the interpretation of the settlement’s scope. While the settlement was designed to resolve all pending disputes linked to the alleged fraud, SEBI’s decision to maintain its proceedings suggests a regulatory insistence on separate accountability or compliance enforcement that may exist outside the criminal settlement. The bench’s remarks point to a broader concern regarding the coordination between judicial directives and regulatory enforcement actions, especially in complex financial crimes involving overlapping jurisdictions.
International Implications and Policy Response
The case underscores the challenges in enforcing large-scale financial settlements where multiple agencies hold jurisdiction. A lack of coordination between the judiciary and regulators can delay the final disbursement of critical funds to public sector banks, potentially undermining the economic intent of such settlements. As the Supreme Court prepares to hear the matter again on March 23, stakeholders including investigative agencies and financial institutions are awaiting clarity on whether judicial settlements will indeed provide a conclusive end to such high-profile fraud cases.
Sources
This report draws on records from the Supreme Court of India, public filings from the Securities and Exchange Board of India (SEBI), and official statements from the Government of India regarding the Sterling Biotech settlement.
